What the Data Shows Hair loss on semaglutide gets blamed on the drug
This includes talking about things like how the injury occurred, which treatments have already been attempted, and how the injury is affecting the patients daily life
What We Still Need Prospective, randomized trials in breast cancer survivors Mechanistic research to understand why some lab results show opposite effects More diversity in study populations by race, age, and socioeconomic status Long-term follow-up to track recurrence and survival outcomes The Bottom Line GLP-1 receptor agonists are transforming obesity care
These physiological alterations yield atypical patterns of tracer uptake, complicating the clear differentiation between malignant versus benign or inflammatory processes
The variability in dosage, duration of treatment, and experimental models used in different studies contributes to the difficulty in drawing definitive conclusions